Exploration of Biomarkers in Familial Hypercholesterolemia (FH) - FH-001

Beren Therapeutics P.B.C.0 个研究点目标入组 25 人开始时间: 待定最近更新: 2024年4月15日

试验速览

暂无简介。

•1. Patients clinically diagnosed using regional diagnostic criteria (e.g., Simon
•Broome, Dutch Lipid Network, MEDPED, etc.) and/or genetically
•confirmed diagnosis of Familial Hypercholesterolemia (FH)
•2. >=12 years of age
•3. Triglycerides <= 300 mg/dL
•4. Average Fasting LDL-C levels:
•o >=190mg/dL within last 30 days for untreated adults
•o >=150mg/dL within last 30 days for untreated children
•o >=160mg/dL within last 30 days for stably treated patients (adults &

•1. Conditions or circumstances that, in the opinion of the Investigator, could
•interfere with or confound study results, or preclude informed consent.
•2. Liver transplant recipients.
•3. Patients who have undergone partial ileal bypass surgery.
•4. Patients with evidence in medical history of chronic HBV infection, HCV
•infection, or HIV infection
•5.Patients who are currently participating or have participated in a clinical
•trial in which investigational intervention was administered within 12 weeks or
•5 half-lives, whichever is longer, of Screening in this clinical study.

发起方

Beren Therapeutics P.B.C.